Literature DB >> 25029093

Hereditary disorders affecting the lacrimal system.

Richard C Allen1.   

Abstract

PURPOSE OF REVIEW: Encountering a patient with lacrimal dysgenesis or agenesis is not an uncommon occurrence in an oculoplastic surgeon's practice. Eliciting a hereditary component in patients with lacrimal disorders is helpful in determining the underlying cause of the condition. The purpose of this review is to assist the clinician in understanding and categorizing those lacrimal disorders with a hereditary component. RECENT
FINDINGS: Compared with genetic diseases which affect the eyelids, hereditary disorders that affect the lacrimal system are fewer in number. These disorders can be categorized into the following groups: fibroblast growth factor 10 associated disorders, tumor protein p63 associated disorders, disorders associated with the development of the branchial apparatus, and disorders associated with autonomic dysfunction. In addition, there are a number of reports of inherited disorders affecting the lacrimal system that have not been elucidated molecularly.
SUMMARY: Inherited disorders that affect the lacrimal system are limited in number. Knowledge of these disorders by the oculoplastic surgeon may aid in the correct diagnosis, which in turn will allow appropriate treatment of these patients.

Entities:  

Mesh:

Year:  2014        PMID: 25029093     DOI: 10.1097/ICU.0000000000000092

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  2 in total

1.  Comparative Proteomics of Mouse Tears and Saliva: Evidence from Large Protein Families for Functional Adaptation.

Authors:  Robert C Karn; Christina M Laukaitis
Journal:  Proteomes       Date:  2015-09-07

2.  Malformation of Tear Ducts Underlies the Epiphora and Precocious Eyelid Opening in Prickle 1 Mutant Mice: Genetic Implications for Tear Duct Genesis.

Authors:  Jiali Ru; Dianlei Guo; Jiaying Fan; Jiao Zhang; Rong Ju; Hong Ouyang; Lai Wei; Yizhi Liu; Chunqiao Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.